Hengrui’s 2026 BMI Listings Propel China Drug Sales by $30–$50 M
Jiangsu Hengrui’s new 2026 BMI and commercial drug directory inclusions boost access, lower out‑of‑pocket costs, and could drive $30‑$50 million in sales over 18‑24 months.
- JIANGSU HENGRUI PHARMACEUT-H
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read
